Case number 1:23-cv-00714
Intercept Pharmaceuticals, Inc. et al v. Zenara Pharma Private Limited > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 6, 2024 | N/A | CASE CLOSED per D.I. 104 in Lead Case C.A. No. 22-1215 (MN). (dlw) (Entered: 03/06/2024) (0) |
| Mar 6, 2024 | 12 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Consent Judgment)(mdb) (Entered: 03/06/2024) (0) |
| Aug 15, 2023 | 10 | STIPULATION and [Proposed] Order to Consolidate by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 08/15/2023) (4) |
| Aug 15, 2023 | 11 | SO ORDERED re (46 in 1:22-cv-01215-MN, 10 in 1:23-cv-00714-MN) Stipulation and Order to Consolidate. These cases are consolidated for all purposes. Set/Reset Scheduling Order Deadlines - Amended Pleadings due by 1/12/2024. Fact Discovery completed by 2/23/2024. Opening Expert Reports due by 8/23/2024. Rebuttal Expert Reports due by 9/27/2024. Reply Expert Reports due by 10/25/2024. Expert Discovery due by 11/22/2024. Joinder of Parties due by 1/12/2024. Claim Construction Opening Brief served by 5/3/2024. Claim Construction Answering Brief served by 5/24/2024. Claim Construction Reply Brief served by 6/11/2024. Claim Construction Surreply Brief served by 6/25/2024. Joint Claim Construction Brief filed by 7/1/2024. A Markman Hearing is set for 7/31/2024 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika., A Pretrial Conference is set for 3/11/2025 at 04:30 PM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 3/17/2025 at 09:00 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 8/15/2023. (dlw) (Entered: 08/15/2023) (4) |
| Aug 15, 2023 | N/A | Case associated with lead case: Create association to 1:22-cv-01215-MN. (dlw) (Entered: 08/15/2023) (0) |
| Jul 13, 2023 | N/A | Pro Hac Vice Attorney Julia S. Kim, Edward D. Pergament, Dmitry V. Shelhoff, and Kenneth S. Canfield for Zenara Pharma Private Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 07/13/2023) (0) |
| Jul 12, 2023 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff, Kenneth S. Canfield, Edward D. Pergament and Julia S. Kim - filed by Zenara Pharma Private Limited. (Attachments: # 1 Certification of Dmitry V. Shelhoff, # 2 Certification of Kenneth S. Canfield, # 3 Certification of Edward D. Pergament, # 4 Certification of Julia S. Kim)(Delcollo, Renee) (Entered: 07/12/2023) (0) |
| Jul 12, 2023 | N/A | SO ORDERED re 9 MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff, Kenneth S. Canfield, Edward D. Pergament and Julia S. Kim filed by Zenara Pharma Private Limited. ORDERED by Judge Maryellen Noreika on 7/12/2023. (dlw) (Entered: 07/12/2023) (0) |
| Jul 7, 2023 | 7 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited.(Delcollo, Renee) Modified on 7/10/2023 (dlw). (Entered: 07/07/2023) (11) |
| Jul 7, 2023 | 8 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Biophore India Pharmaceuticals Private Ltd. for Zenara Pharma Private Limited filed by Zenara Pharma Private Limited. (Schladweiler, Benjamin) (Entered: 07/07/2023) (1) |
| Jul 5, 2023 | N/A | Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) (Entered: 07/05/2023) (0) |
| Jun 30, 2023 | 1 | Complaint* (1) |
| Jun 30, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 06/30/2023) (3) |
| Jun 30, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 06/21/2023. Date of Expiration of Patent: 02/21/2027.Thirty Month Stay Deadline: 12/21/2025. (vfm) (Entered: 06/30/2023) (1) |
| Jun 30, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE 48,286. (vfm) (Entered: 06/30/2023) (1) |
| Jun 30, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Intercept Pharmaceuticals for Intercept Pharma Europe Limited filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (vfm) (Entered: 06/30/2023) (1) |
| Jun 30, 2023 | 6 | Summons Issued as to Zenara Pharma Private Limited on 6/30/2023. (vfm) (Entered: 06/30/2023) (2) |
